Yıl: 2019 Cilt: 21 Sayı: 1 Sayfa Aralığı: 25 - 30 Metin Dili: İngilizce DOI: 10.14744/AnatolJCardiol.2018.50880 İndeks Tarihi: 24-10-2020

The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators

Öz:
Objective: Acute heart failure (AHF) is a life-threatening clinical syndrome characterized by rapid onset of heart failure (HF) symptoms and signsand requires urgent therapy. The aim of the present study was to evaluate the overall clinical characteristics, management, and in-hospital outcomes of hospitalized patients with AHF in a large sample of Turkish population.Methods: The Journey HF-TR study is a cross-sectional, multicenter, non-invasive and observational trial. Patients who were hospitalized witha diagnosis of AHF in the intensive care unit (ICU)/coronary care unit and cardiology wards between September 2015 and September 2016 wereincluded in our study.Results: A total of 1606 (male: 57.2%, mean age: 67.8±13 years) patients who were diagnosed with AHF were enrolled in the study. Seventeenpercent of the patients were admitted to the hospital with a diagnosis of new onset AHF. Hypertension (67%) and coronary artery disease (CAD)(59.6%) were the most frequent underlying diseases. Acute coronary syndrome accompanying HF (14.7%), infection (29.3%), arrhythmia (25.1%),renal dysfunction (23%), and non-compliance with medication (23.8%) were the precipitating factors. The median length of stay in the ICU was 3days (interquartile range, IQR 1–72) and 7 days (IQR 1–72) for in-hospital journey. The guideline recommended medications were less likely usedin our patient population (<73%) before admission and were similar to European and US registers at discharge. The in-hospital mortality ratewas 7.6%. Hypertension and CAD were the most frequent underlying diseases in our population similar to other European surveys. Although ourstudy population was younger than other registers, in-hospital mortality was high.Conclusion: Analyses of such real-world data will help to prepare a national database and distinctive diagnosis and treatment algorithms andto provide observing compliance with the current European Society of Cardiology guidelines for more effective management of HF. (Anatol JCardiol 2019; 21: 25-30)
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.
  • 2. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-25.
  • 3. Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121: e46–e215.
  • 4. Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Redford MJ, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997; 157: 99-104.
  • 5. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solel A, Aguilar JC, et al. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-63.
  • 6. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al.; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-36.
  • 7. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, et al.; Heart Failure Association of ESC (HFA). EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010; 12: 1076-84.
  • 8. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al.; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-16.
  • 9. Galvao M, Kalman J, DeMarco T, Fonarow GC, Galvin C, Ghali JK, et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Card Fail 2006; 12: 100-7.
  • 10. Tokgözoğlu L, Kaya EB, Erol C, Ergene O; EUROASPIRE III Turkey Study Group. [EUROASPIRE III: a comparison between Turkey and Europe]. Turk Kardiyol Dern Ars 2010; 38: 164-72.
  • 11. Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al.; OPTIMIZE-HF Investigators and Coordinators. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 2008; 101: 223-30.
  • 12. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 2002; 4: 681-6.
  • 13. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 1992; 21: 669-74.
  • 14. Farmakis D, Parissis J, Lekakis J, Filippatos G. Acute heart failure: Epidemiology, risk factors, and prevention. Rev Esp Cardiol (Engl Ed) 2015; 68: 245-8.
  • 15. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopantin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail 2009; 15: 256-64.
  • 16. Kaya H, Yilmaz MB. In-hospital journey of patients with heart failure. International Journal of the Cardiovascular Academy 2015; 1: 31-3.
  • 17. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, et al.; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112: 3738-44.
  • 18. Eren M, Zoghi M, Tuncer M, Çavuşoğlu Y, Demirbağ R, Şahin M, et al.; TAKTIK Investigators. Turkish registry for diagnosis and treatment of acute heart failure: TAKTIK study. Turk Kardiyol Dern Ars 2016; 44: 637-46.
  • 19. Chioncel O, Ambrosy AP, Bubenek S, Filipescu D, Vinereanu D, Petris A, et al.; Romanian Acute Heart Failure Syndromes study investigators. Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry. J Cardiovasc Med (Hagerstown) 2016; 17: 92- 104.
  • 20. Moleerergpoom W, Hengrussamee K, Piyayotai D, Jintapakorn W, Sukhum P, Kunjara-Na-Ayudhya R, et al. Predictors of in-hospital mortality in acute decompensated heart failure (Thai ADHERE). J Med Assoc Thai 2013; 96: 157-64.
APA Sinan U, Ekmekçi A, Ozbay B, AKÇAY AKYILDIZ F, BEKAR L, KOZA Y, Bolat İ, Kocabas U, ZOGHİ M (2019). The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. , 25 - 30. 10.14744/AnatolJCardiol.2018.50880
Chicago Sinan Umit Yasar,Ekmekçi Ahmet,Ozbay Benay,AKÇAY AKYILDIZ Filiz,BEKAR Lütfü,KOZA Yavuzer,Bolat İsmail,Kocabas Umut,ZOGHİ Mehdi The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. (2019): 25 - 30. 10.14744/AnatolJCardiol.2018.50880
MLA Sinan Umit Yasar,Ekmekçi Ahmet,Ozbay Benay,AKÇAY AKYILDIZ Filiz,BEKAR Lütfü,KOZA Yavuzer,Bolat İsmail,Kocabas Umut,ZOGHİ Mehdi The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. , 2019, ss.25 - 30. 10.14744/AnatolJCardiol.2018.50880
AMA Sinan U,Ekmekçi A,Ozbay B,AKÇAY AKYILDIZ F,BEKAR L,KOZA Y,Bolat İ,Kocabas U,ZOGHİ M The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. . 2019; 25 - 30. 10.14744/AnatolJCardiol.2018.50880
Vancouver Sinan U,Ekmekçi A,Ozbay B,AKÇAY AKYILDIZ F,BEKAR L,KOZA Y,Bolat İ,Kocabas U,ZOGHİ M The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. . 2019; 25 - 30. 10.14744/AnatolJCardiol.2018.50880
IEEE Sinan U,Ekmekçi A,Ozbay B,AKÇAY AKYILDIZ F,BEKAR L,KOZA Y,Bolat İ,Kocabas U,ZOGHİ M "The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators." , ss.25 - 30, 2019. 10.14744/AnatolJCardiol.2018.50880
ISNAD Sinan, Umit Yasar vd. "The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators". (2019), 25-30. https://doi.org/10.14744/AnatolJCardiol.2018.50880
APA Sinan U, Ekmekçi A, Ozbay B, AKÇAY AKYILDIZ F, BEKAR L, KOZA Y, Bolat İ, Kocabas U, ZOGHİ M (2019). The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. The Anatolian Journal of Cardiology, 21(1), 25 - 30. 10.14744/AnatolJCardiol.2018.50880
Chicago Sinan Umit Yasar,Ekmekçi Ahmet,Ozbay Benay,AKÇAY AKYILDIZ Filiz,BEKAR Lütfü,KOZA Yavuzer,Bolat İsmail,Kocabas Umut,ZOGHİ Mehdi The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. The Anatolian Journal of Cardiology 21, no.1 (2019): 25 - 30. 10.14744/AnatolJCardiol.2018.50880
MLA Sinan Umit Yasar,Ekmekçi Ahmet,Ozbay Benay,AKÇAY AKYILDIZ Filiz,BEKAR Lütfü,KOZA Yavuzer,Bolat İsmail,Kocabas Umut,ZOGHİ Mehdi The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. The Anatolian Journal of Cardiology, vol.21, no.1, 2019, ss.25 - 30. 10.14744/AnatolJCardiol.2018.50880
AMA Sinan U,Ekmekçi A,Ozbay B,AKÇAY AKYILDIZ F,BEKAR L,KOZA Y,Bolat İ,Kocabas U,ZOGHİ M The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. The Anatolian Journal of Cardiology. 2019; 21(1): 25 - 30. 10.14744/AnatolJCardiol.2018.50880
Vancouver Sinan U,Ekmekçi A,Ozbay B,AKÇAY AKYILDIZ F,BEKAR L,KOZA Y,Bolat İ,Kocabas U,ZOGHİ M The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators. The Anatolian Journal of Cardiology. 2019; 21(1): 25 - 30. 10.14744/AnatolJCardiol.2018.50880
IEEE Sinan U,Ekmekçi A,Ozbay B,AKÇAY AKYILDIZ F,BEKAR L,KOZA Y,Bolat İ,Kocabas U,ZOGHİ M "The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators." The Anatolian Journal of Cardiology, 21, ss.25 - 30, 2019. 10.14744/AnatolJCardiol.2018.50880
ISNAD Sinan, Umit Yasar vd. "The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators". The Anatolian Journal of Cardiology 21/1 (2019), 25-30. https://doi.org/10.14744/AnatolJCardiol.2018.50880